Type 1 Gaucher disease (GDI) is the most common form of the disorder with an incidence of 1 in 50,000 births. The underlying problem is accumulation of glucocerebroside due to a lysosomal enzyme deficiency, which may cause oxidative stress and inflammation contributing to the onset of symptoms. Standard texts state that GDI does not involve the brain. This view is now being challenged based on imaging, postmortem, and clinical studies. For example, individuals with GDI have an elevated risk of Parkinson's disease, indicating brain involvement. Current therapies significantly improved outcomes, but do not completely return glucocerebroside levels to the normal range nor completely resolve symptoms or prevent continuing tissue injury. Thus, additional treatments that target oxidative stress and inflammation have the potential to ameliorate both systemic and brain symptoms and may alter disease progression. Our central hypothesis is that relative to healthy subjects, GDI patients exhibit increased systemic and brain oxidative stress and inflammation. Further, we hypothesize that antioxidant/anti-inflammatory therapy can improve oxidative stress/inflammation in GDI patients. We propose the following aims to test these hypotheses.
In Aim 1 we will compare in GDI patients and healthy subjects oxidative stress and inflammatory markers in plasma and blood using bioanalytical methods and in brains using magnetic resonance spectroscopy.
In Aim 2 we will study GDI patients to: a) determine if oral N-acetylcysteine (NAC) improves plasma, blood and brain measures of oxidative stress and inflammation;b) evaluate correlations between plasma/blood NAC, cysteine, and glutathione (GSH) concentrations with brain GSH levels;and c) characterize NAC and GSH pharmacokinetics using validated bioanalytical methods and construct models linking pharmacokinetics with biomarkers. Impact: our results will lead to a greater understanding of GDI pathophysiology;identify potential biomarkers for use in diagnosis, monitoring disease progression, and therapy;provide information needed to determine if phase III clinical trials of NAC or other antioxidants/anti-inflammatories are warranted; and guide study design and sample size estimation.

Public Health Relevance

Current therapeutic interventions for GD1 have improved outcomes, but patients continue to suffer from persistent symptoms such as pain, fatigue, and joint stiffness that limit their quality of life and substantially increase health care costs. Oxidative stress and/or inflammation may cause or contribute to these symptoms, but systematic studies are needed to determine if this is the case. The availability of low cost, safe antioxidant/anti-inflammatory therapy offers the potential to correct this problem and improve outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54NS065768-06
Application #
8907066
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Morris, Jill A
Project Start
Project End
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
6
Fiscal Year
2014
Total Cost
$55,328
Indirect Cost
$18,928
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Jarnes Utz, Jeanine R; Kim, Sarah; King, Kelly et al. (2017) Infantile gangliosidoses: Mapping a timeline of clinical changes. Mol Genet Metab 121:170-179
Whitley, Chester B (2017) WORLDSymposiumâ„¢ 2017 Introduction. Mol Genet Metab 120:S2-S6
Ou, Li; Przybilla, Michael J; Koniar, Brenda et al. (2017) RTB lectin-mediated delivery of lysosomal ?-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Mol Genet Metab :
Solomon, Melani; Muro, Silvia (2017) Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev 118:109-134
Mauer, Michael; Sokolovskiy, Alexey; Barth, Jay A et al. (2017) Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment. J Med Genet 54:781-786
Eisengart, Julie B; Jarnes, Jeanine; Ahmed, Alia et al. (2017) Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome. Mol Genet Metab Rep 13:64-68
Rairikar, Mugdha; Kazi, Zoheb B; Desai, Ankit et al. (2017) High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. Mol Genet Metab 122:76-79
Ou, Li; Przybilla, Michael J; Whitley, Chester B (2017) Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis. Mol Genet Metab 120:101-110
Rairikar, Mugdha V; Case, Laura E; Bailey, Lauren A et al. (2017) Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G ""late-onset"" GAA variant. Mol Genet Metab 122:99-107
McIntosh, Paul T; Hobson-Webb, Lisa D; Kazi, Zoheb B et al. (2017) Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab :

Showing the most recent 10 out of 102 publications